Schaper Benz & Wise Investment Counsel Inc. WI Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schaper Benz & Wise Investment Counsel Inc. WI boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,098 shares of the biopharmaceutical company's stock after purchasing an additional 764 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI's holdings in Regeneron Pharmaceuticals were worth $12,747,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares during the period. Principal Securities Inc. boosted its position in Regeneron Pharmaceuticals by 43.9% in the fourth quarter. Principal Securities Inc. now owns 898 shares of the biopharmaceutical company's stock valued at $640,000 after buying an additional 274 shares during the last quarter. Allworth Financial LP increased its holdings in Regeneron Pharmaceuticals by 35.1% in the 4th quarter. Allworth Financial LP now owns 958 shares of the biopharmaceutical company's stock worth $651,000 after buying an additional 249 shares during the period. Americana Partners LLC raised its position in Regeneron Pharmaceuticals by 11.5% during the 4th quarter. Americana Partners LLC now owns 350 shares of the biopharmaceutical company's stock worth $249,000 after buying an additional 36 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $350,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $4.72 during trading on Wednesday, reaching $513.58. The stock had a trading volume of 841,026 shares, compared to its average volume of 884,759. The business has a fifty day moving average price of $561.15 and a 200-day moving average price of $645.97. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a market cap of $55.45 billion, a PE ratio of 13.07, a PEG ratio of 1.86 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company earned $9.55 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on REGN shares. UBS Group cut their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Citigroup decreased their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 2nd. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Bank of America decreased their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.